COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Phase 2 Study of Oral MKC-1 in Patients With Ovarian or Endometrial Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00607607
Recruitment Status : Completed
First Posted : February 6, 2008
Last Update Posted : January 20, 2012
Information provided by:
CASI Pharmaceuticals, Inc.

Brief Summary:
Patients will be treated with MKC-1, twice daily for 14 consecutive days every four weeks (a cycle of MKC-1 chemotherapy), until disease progression or unacceptable toxicities. Patients will be stratified to Arm A (ovarian cancer) or Arm B (endometrial cancer), and will receive identical treatment regimens.

Condition or disease Intervention/treatment Phase
Ovarian Cancer Endometrial Cancer Drug: MKC-1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 44 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Study of Oral MKC-1 Administered Twice Daily for 14 Consecutive Days Every 4 Weeks in Patients With Recurrent or Resistant Epithelial Ovarian Cancer or Advanced Endometrial Cancer
Study Start Date : January 2008
Actual Primary Completion Date : June 2011
Actual Study Completion Date : January 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Ovarian Cancer

Arm Intervention/treatment
Experimental: A
Ovarian Cancer Patients
Drug: MKC-1
capsules, provided 125 mg/m2 BID x 14 days in 28 day cycles

Experimental: B
Endometrial Cancer Patients
Drug: MKC-1
capsules, provided 125 mg/m2 BID x 14 days in 28 day cycles

Primary Outcome Measures :
  1. Tumor response rate (based on tumor measurements according to the RECIST criteria) or CA-125 [ Time Frame: Every 4 to 8 weeks ]

Secondary Outcome Measures :
  1. Time to progression [ Time Frame: Time of progression ]
  2. Adverse events spontaneously declared by the patients or noted during physical examination and laboratory tests. [ Time Frame: As reported ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Provide written informed consent (and HIPAA authorization for release of protected health information, as applicable) prior to any study related assessments.
  2. Histologically confirmed epithelial ovarian cancer, primary peritoneal carcinomatosis, fallopian tube cancers, or endometrial cancer.
  3. Age > 18 years at the time of consent.
  4. Arm A: Ovarian Cancer Patients:

    • Must have failed at least one prior platinum based and one taxane based chemotherapeutic regimen. [Platinum failure is defined as platinum-refractory (progression while receiving a platinum-containing regimen) or platinum-resistant (disease progression within 6 months from completion of platinum containing regimen)].
    • Have measurable disease according to RECIST or CA 125 criteria according to GCIG (CA-125 value of > 2 xULN).
    • Have no more than 3 prior regimens for their disease.

    Arm B: Endometrial Cancer Patients:

    • Have no more than 3 prior regimens for their disease
    • Have measurable disease according to RECIST.
  5. ECOG performance status of 0, 1, or 2.
  6. The following laboratory results, within 10 days of MKC-1 administration:

    • Hemoglobin greater than or equal to 90 g/L (9 g/dL)
    • Absolute neutrophil count greater than or equal to 1.5 x 109/L
    • Platelet count greater than or equal to 100 x 109/L
    • Serum creatinine less than or equal to 1.5 x ULN (upper limit of normal)
    • AST less than or equal to 2.5 x ULN
    • Serum Albumin greater than or equal to 30 g/L (3.0 g/dL)
    • Total bilirubin less than or equal to ULN

Exclusion Criteria:

  1. Administration of cancer specific therapy within the following periods prior to study drug initiation:

    • chemotherapy less than 3 weeks prior;
    • hormonal therapy less than one week prior;
    • radiation therapy less than 2 weeks prior.
  2. Requirement for paracentesis > 2 liters/week.
  3. Pregnant or breast-feeding women. Female patients must be postmenopausal, surgically sterile, or they must agree to use a physical method of contraception. Female patient with childbearing potential must have a negative pregnancy test within 10 days before the first MKC-1 administration.
  4. Known CNS metastases unless treated, clinically stable, and not requiring steroids.
  5. Clinical evidence of significant bowel obstruction, active uncontrolled malabsorption syndromes, or a history of total gastrectomy.
  6. Uncontrolled hypercalcemia (serum calcium-corrected > 3 mmol/L [12 mg/dL]).
  7. Serious cardiac condition (Class III/IV congestive heart failure according to New York Heart Association classification); documented acute myocardial infarction within the previous 6 months.
  8. Any medical conditions that, in the investigator's opinion, would impose excessive risk to the patient. These include: infection requiring parenteral or oral anti-infective treatment, any altered mental status, or any psychiatric condition that would interfere with the understanding of the informed consent.
  9. Patients with previous malignancies unless free of recurrence for at least 5 years except cured basal cell carcinoma of the skin or carcinoma-in-situ of the uterine cervix.
  10. Treatment with antiretroviral therapy metabolized through CYP3A4 (including indinavir, nelfinavir, ritonavir and saquinavir).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00607607

Layout table for location information
Canada, Ontario
Juravinski Cancer Centre
Hamilton, Ontario, Canada, L8V 5C2
Cancer Centre of Southeastern Ontario at Kingston General Hospital
Kingston, Ontario, Canada, K7L 5P9
London Health Sciences Centre
London, Ontario, Canada, N6A 4L6
Credit Valley Hospital
Mississauga, Ontario, Canada, L5M 2N1
Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9
Canada, Quebec
Hopital Notre-Dame du CHUM
Montreal, Quebec, Canada, H2L 4M1
Sponsors and Collaborators
CASI Pharmaceuticals, Inc.
Layout table for investigator information
Principal Investigator: Amit Oza, MD Princess Margaret Hospital, Canada
Layout table for additonal information
Responsible Party: Carolyn Sidor, MD, MBA, EntreMed, Inc. Identifier: NCT00607607    
Other Study ID Numbers: MKC-103
First Posted: February 6, 2008    Key Record Dates
Last Update Posted: January 20, 2012
Last Verified: January 2012
Keywords provided by CASI Pharmaceuticals, Inc.:
ovarian cancer
endometrial cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Endometrial Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Uterine Neoplasms
Uterine Diseases